Biblio

Found 23 results
Filters: Author is Streicher, John M  [Clear All Filters]
2022
Fullerton EF, Karom MC, Streicher JM, Young LJ, Murphy AZ.  2022.  Age-Induced Changes in μ-Opioid Receptor Signaling in the Midbrain Periaqueductal Gray of Male and Female Rats.. J Neurosci. 42(32):6232-42.
Stefanucci A, Valle ADella, Scioli G, Marinaccio L, Pieretti S, Minosi P, Szucs E, Benyhe S, Masci D, Tanguturi P et al..  2022.  Discovery of κ Opioid Receptor (KOR)-Selective d-Tetrapeptides with Improved Antinociceptive Effect after Peripheral Administration.. ACS Med Chem Lett. 13(11):1707-1714.
Wahl JR, Vivek A, Palomino SM, Almuslim M, Cottier KE, Langlais PR, Streicher JM, Vanderah TW, Liktor-Busa E, Largent-Milnes TM.  2022.  Extracellular Alterations in pH and K+ Modify the Murine Brain Endothelial Cell Total and Phospho-Proteome.. Pharmaceutics. 14(7)
Palomino SM, Levine AA, Wahl J, Liktor-Busa E, Streicher JM, Largent-Milnes TM.  2022.  Inhibition of HSP90 Preserves Blood-Brain Barrier Integrity after Cortical Spreading Depression.. Pharmaceutics. 14(8)
2020
Stine C, Coleman DL, Flohrschutz AT, Thompson AL, Mishra S, Blagg BS, Largent-Milnes TM, Lei W, Streicher JM.  2020.  Heat shock protein 90 inhibitors block the antinociceptive effects of opioids in mouse chemotherapy-induced neuropathy and cancer bone pain models.. Pain. 161(8):1798-1807.
2018
Edwards KA, Havelin JJ, McIntosh MI, Ciccone HA, Pangilinan K, Imbert I, Largent-Milnes TM, King T, Vanderah TW, Streicher JM.  2018.  A Kappa Opioid Receptor Agonist Blocks Bone Cancer Pain Without Altering Bone Loss, Tumor Size, or Cancer Cell Proliferation in a Mouse Model of Cancer-Induced Bone Pain.. J Pain. 19(6):612-625.
2017
Stefanucci A, Lei W, Hruby VJ, Macedonio G, Luisi G, Carradori S, Streicher JM, Mollica A.  2017.  Fluorescent-labeled bioconjugates of the opioid peptides biphalin and DPDPE incorporating fluorescein-maleimide linkers.. Future Med Chem. 9(9):859-869.
Lei W, Mullen N, McCarthy S, Brann C, Richard P, Cormier J, Edwards K, Bilsky EJ, Streicher JM.  2017.  Heat-shock protein 90 (Hsp90) promotes opioid-induced anti-nociception by an ERK mitogen-activated protein kinase (MAPK) mechanism in mouse brain.. J Biol Chem. 292(25):10414-10428.
Xie JY, De Felice M, Kopruszinski CM, Eyde N, LaVigne J, Remeniuk B, Hernandez P, Yue X, Goshima N, Ossipov M et al..  2017.  Kappa opioid receptor antagonists: A possible new class of therapeutics for migraine prevention.. Cephalalgia. 37(8):780-794.
Olson KM, Lei W, Keresztes A, LaVigne J, Streicher JM.  2017.  Novel Molecular Strategies and Targets for Opioid Drug Discovery for the Treatment of Chronic Pain.. Yale J Biol Med. 90(1):97-110.
2016
Zhang Y, Williams DA, Zaidi SA, Yuan Y, Braithwaite A, Bilsky EJ, Dewey WL, Akbarali HI, Streicher JM, Selley DE.  2016.  17-Cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6β-(4'-pyridylcarboxamido)morphinan (NAP) Modulating the Mu Opioid Receptor in a Biased Fashion.. ACS Chem Neurosci. 7(3):297-304.
2015
Stevenson GW, Luginbuhl A, Dunbar C, LaVigne J, Dutra J, Atherton P, Bell B, Cone K, Giuvelis D, Polt R et al..  2015.  The mixed-action delta/mu opioid agonist MMP-2200 does not produce conditioned place preference but does maintain drug self-administration in rats, and induces in vitro markers of tolerance and dependence.. Pharmacol Biochem Behav. 132:49-55.
Frankowski KJ, Slauson SR, Lovell KM, Phillips AM, Streicher JM, Zhou L, Whipple DA, Schoenen FJ, Prisinzano TE, Bohn LM et al..  2015.  Potency enhancement of the κ-opioid receptor antagonist probe ML140 through sulfonamide constraint utilizing a tetrahydroisoquinoline motif.. Bioorg Med Chem. 23(14):3948-56.
2014
Zhang Y, Braithwaite A, Yuan Y, Streicher JM, Bilsky EJ.  2014.  Behavioral and cellular pharmacology characterization of 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6α-(isoquinoline-3'-carboxamido)morphinan (NAQ) as a mu opioid receptor selective ligand.. Eur J Pharmacol. 736:124-30.
2013
Zhou L, Lovell KM, Frankowski KJ, Slauson SR, Phillips AM, Streicher JM, Stahl E, Schmid CL, Hodder P, Madoux F et al..  2013.  Development of functionally selective, small molecule agonists at kappa opioid receptors.. J Biol Chem. 288(51):36703-16.
Schmid CL, Streicher JM, Groer CE, Munro TA, Zhou L, Bohn LM.  2013.  Functional selectivity of 6'-guanidinonaltrindole (6'-GNTI) at κ-opioid receptors in striatal neurons.. J Biol Chem. 288(31):22387-98.
2012
Béguin C, Potuzak J, Xu W, Liu-Chen L-Y, Streicher JM, Groer CE, Bohn LM, Carlezon WA, Cohen BM.  2012.  Differential signaling properties at the kappa opioid receptor of 12-epi-salvinorin A and its analogues.. Bioorg Med Chem Lett. 22(2):1023-6.
Frankowski KJ, Hedrick MP, Gosalia P, Li K, Shi S, Whipple D, Ghosh P, Prisinzano TE, Schoenen FJ, Su Y et al..  2012.  Discovery of Small Molecule Kappa Opioid Receptor Agonist and Antagonist Chemotypes through a HTS and Hit Refinement Strategy.. ACS Chem Neurosci. 3(3):221-236.
2011
Tarselli MA, Raehal KM, Brasher AK, Streicher JM, Groer CE, Cameron MD, Bohn LM, Micalizio GC.  2011.  Synthesis of conolidine, a potent non-opioid analgesic for tonic and persistent pain.. Nat Chem. 3(6):449-53.
2010
Streicher JM, Ren S, Herschman H, Wang Y.  2010.  MAPK-activated protein kinase-2 in cardiac hypertrophy and cyclooxygenase-2 regulation in heart.. Circ Res. 106(8):1434-43.
Papanicolaou KN, Streicher JM, Ishikawa T-O, Herschman H, Wang Y, Walsh K.  2010.  Preserved heart function and maintained response to cardiac stresses in a genetic model of cardiomyocyte-targeted deficiency of cyclooxygenase-2.. J Mol Cell Cardiol. 49(2):196-209.
2004
Huan J-Y, Streicher JM, Bleyle LA, Koop DR.  2004.  Proteasome-dependent degradation of cytochromes P450 2E1 and 2B1 expressed in tetracycline-regulated HeLa cells.. Toxicol Appl Pharmacol. 199(3):332-43.
2002
Bethea CL, Lu NZ, Gundlah C, Streicher JM.  2002.  Diverse actions of ovarian steroids in the serotonin neural system.. Front Neuroendocrinol. 23(1):41-100.